UC, UC Health to launch Phase 3 clinical trial for COVID-19 vaccine
Vaccine uses a genetic code to produce proteins that may generate protective antibodies
Researchers at the University of Cincinnati and UC Health will host a Phase 3 clinical trial to evaluate the effectiveness of a vaccine for COVID-19, the respiratory illness caused by the novel coronavirus SARS-CoV-2.
UC is one of approximately 90 sites across the United States selected for the study, which will administer the vaccine candidate mRNA-1273 to volunteer participants and monitor its efficacy in eliciting an immune response that provides protection from COVID-19. The National Institute of Allergy and Infectious Diseases, (NIAID), part of the National Institutes of Health, is funding the study.
Carl Fichtenbaum, MD, of the UC College of Medicine Division of Infectious Diseases, medical director of the COVID-19 vaccine trial. Photo/Colleen Kelley/UC Creative + Brand
“UC was chosen because we have a proven track record of high-quality research and are the number one site in the NIAID-funded, AIDS Clinical Trials Group in the U.S. We are proud to bring leading-edge research to Cincinnati so that we can help our community battle the COVID-19 pandemic and be part of the solution,” said Carl Fichtenbaum, MD, professor in the Division of Infectious Diseases at the UC College of Medicine and a UC Health physician.
Fichtenbaum is co-investigator of the study and will serve as medical director.
Read the full story here.
Featured photo of COVID-19 vials by Colleen Kelley/UC Creative + Brand
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up on all UC's COVID-19 stories, read more #UCtheGood content, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
Related Stories
Tips to reduce alcohol use
January 13, 2025
The University of Cincinnati's Chris Tuell was featured in a Fox News article discussing tips on how to reduce alcohol use following the recent Surgeon General's advisory about alcohol use and cancer risk.
Should the FDA reconsider antidepressant boxed warnings?
January 9, 2025
The University of Cincinnati's Jeffrey Strawn, MD, spoke with Medscape about whether the Food and Drug Administration should reevaluate boxed warnings on antidepressants linking the medications to an increased risk for suicidal thoughts and behaviors in young people.
Bridging health care and legislation: How nursing expertise can...
January 7, 2025
When Rachel Baker, PhD, RN, a University of Cincinnati (UC) bachelor's and PhD in nursing graduate, joined the Ohio House of Representatives in January 2023, she looked forward to leveraging her relationship-building and advocacy skills, as well as using evidence-based and data-driven approaches to policymaking.